Heart Transplant clinical trials at University of California Health
6 in progress, 2 open to eligible people
Allograft Dysfunction in Heart Transplant
open to eligible people ages 18 years and up
The investigators will evaluate for early evidence of cardiac allograft dysfunction by cardiac MRI and single cell sequencing to determine underlying molecular and macroscopic causes.
at UCSD
Diagnostic and Therapeutic Applications of Microarrays in Heart Transplantation
open to eligible people ages 18 years and up
Demonstrate the impact of the Molecular Microscope Diagnostic System as the standard of care for heart transplant patients.
at UCLA
Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score
Sorry, in progress, not accepting new patients
The TEAMMATE Trial will enroll 210 pediatric heart transplant patients from 25 centers at 6 months post-transplant and follow each patient for 2.5 years. Half of the participants will receive everolimus and low-dose tacrolimus and the other half will receive tacrolimus and mycophenolate mofetil. The trial will determine which treatment is better at reducing the cumulative risk of coronary artery vasculopathy, chronic kidney disease and biopsy proven-acute cellular rejection without an increase in graft loss due to all causes (e.g. infection, PTLD, antibody mediated rejection).
at UCLA
Tocilizumab in Cardiac Transplantation
Sorry, not currently recruiting here
The purpose of this research study is to see if a study drug called Tocilizumab will, when given with standard anti-rejection medicines, lead to better heart transplantation outcomes at 1 year after the transplant. Specifically, the investigators will evaluate whether taking tocilizumab leads to less rejection, less development of unwanted antibodies, and better heart function.
at UCLA UCSD
Surveillance HeartCare® Outcomes Registry
Sorry, in progress, not accepting new patients
This is an observational registry to assess the clinical utility of surveillance using HeartCare testing services, in association with clinical care of heart transplant recipients.
at UCLA UCSD UCSF
Trifecta-Heart cfDNA-MMDx Study
Sorry, not currently recruiting here
Demonstrate the relationship between DD-cfDNA levels and HLA antibodies in blood transplant recipient and the Molecular Microscope® (MMDx) Diagnostic System results in indication and protocol biopsies from heart transplants.
at UCLA
Our lead scientists for Heart Transplant research studies include Paul Kim, MD Eric D. Adler, MD.
Last updated: